Tag: GlobeNewswire

Key highlights

• Rezolve Ai presents its strategy, growth drivers and full agentic commerce stack to investors today at Nasdaq MarketSite, with live product demonstrations; investors can register here to join online.
• Rezolve Ai’s US AI Visibility Study 2026 finds that 97 of America’s 100 largest retailers publish no way for an AI agent to check out.
• Management will outline Rezolve Ai’s commercial progress, operating priorities and growth strategy as the Company demonstrates its full platform for the agentic commerce economy.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in agentic commerce and AI-powered customer engagement, today hosts its Investor Day at Nasdaq MarketSite in New York City. Management will give investors and analysts the first comprehensive presentation of how Rezolve Ai’s commerce, data and payments capabilities combine into a single platform for the agentic economy. The event is open to in-person and online attendees, who can register here.

To mark the event, Rezolve Ai today publishes the US AI Visibility Study 2026, which examines how the leading AI assistants present 2,047 US companies to consumers. The companies span every member of the S&P 500, all of the NRF Top 100 retailers, 60 large private companies, 362 consumer brands and more than 1,000 other US retailers and listed companies.

The study finds that one in four of these companies is never named by OpenAI, Claude, Perplexity or Gemini, including nearly one in five members of the S&P 500. AI assistants name companies most often while consumers browse, yet 97 of America’s 100 largest retailers publish no way for an AI agent to check out, including 13 that turned automated visitors away. Additionally, most LLMs build their answers almost entirely from third parties, with a company’s own website accounting for just 1.5% of the sources AI cites, and visibility differs from one assistant to the next.

“Every era of commerce has had a gatekeeper. For twenty years it was the search engine. Today it is the AI agent, and it is deciding which brands a customer hears about before they ever reach a store,” said Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai. “This research should be a wake-up call to every boardroom in America. The companies that win the next decade of commerce will be the ones that give AI something it can trust and transact with, and that is precisely what Rezolve Ai was built to provide.”

Rezolve Ai’s platform is designed to enable merchants to supply AI assistants with trusted answers drawn from their own catalog, live pricing and availability. Its agent-ready APIs are designed to help those assistants find products and complete purchases directly. Its commerce-trained brainpowa models interpret shopper intent, while Rezolve Commerce and agentic checkout convert that intent into a sale. Rezolve Pay supports payment optimization, and Rezolve Reward helps drive customer engagement and repeat purchasing.

Rezolve Ai takes the platform to market through three growth engines that reinforce one another: an expanding product suite, distribution through Microsoft, Google, TCS and Tech Mahindra, and the licensing of the data, intelligence and payment rails beneath it to platforms, banks and payment networks.

Investor Day Focus
At Investor Day, management will present Rezolve Ai’s strategy, market opportunity, commercial model and growth drivers. The presentation will focus on the Company’s platform, strategic partnerships, product roadmap, customer adoption, operating discipline and path toward long-term profitable growth. Live demonstrations will show how trusted data infrastructure, proprietary commerce intelligence, auditable agent workflows, customer engagement, transactions and payments connect across the platform.

“I founded Rezolve Ai to give digital commerce what the best stores have always had: an assistant who understands the customer and closes the sale,” said Wagner. “A decade later, AI agents are becoming the largest sales force commerce has ever known, and Rezolve Ai is the infrastructure backbone they run on. Today investors will see a business that has proven it can scale and is now turning that scale into profitability.”

Event details
Date: Tuesday, October 6, 2026
Location: Nasdaq MarketSite, New York City
Schedule: Networking breakfast from 9:00 a.m. EDT; opening remarks and live webcast from 9:45 a.m. EDT, concluding at approximately 1:00 p.m. EDT
Registration: Investors and analysts can attend in person or online and should pre-register at edge.media-server.com/mmc/p/hz8x6poa
Materials: The live webcast, replay and presentation materials will be available on Rezolve Ai’s investor relations website at investor.rezolve.com

About the US AI Visibility Study 2026
The study analyzed how OpenAI, Claude, Perplexity and Gemini, each with web search enabled, respond to unbranded consumer questions about the markets of 2,047 US companies drawn from six public lists, including the S&P 500 and the NRF Top 100. Fieldwork took place between September 23 and October 5, 2026. Full results and methodology are available at aeo-audit.rezolve.com/us.

About Rezolve Ai
Rezolve Ai is the infrastructure backbone powering AI-driven commerce for merchants, financial institutions, hyperscalers and technology companies. Its Brain Suite platform helps retailers, brands and financial institutions transform how consumers search, engage and transact across digital channels.

Rezolve Ai’s proprietary brainpowa™ models are purpose-built for commerce, while TraceWare™ is designed to provide transparency and accountability across agentic AI workflows. Together, Rezolve Ai’s technology enables enterprises to deploy AI that can engage customers, understand intent, support transactions and operate safely at scale.

Headquartered in London with operations across North America, Europe and Asia, Rezolve Ai partners with leading global enterprises to power the future of commerce through AI that sells. Learn more at rezolve.com.

Media contact
Urmee Khan, Group Director of Communications & Corporate Affairs, Rezolve Ai:
urmeekhan@rezolve.com
+44 7576 094 040

Forward-looking statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements about Rezolve Ai’s product plans, platform capabilities, strategic partnerships, market opportunity, growth strategy, profitability, Investor Day presentations and matters described in the U.S. AI Visibility Study 2026. These statements reflect management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described in Rezolve Ai’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Rezolve Ai undertakes no obligation to update them except as required by law.

Over 80 percent say their generation faces unique retirement challenges, with rising health care costs, inflation and Social Security uncertainty reshaping expectations for life after work

WEST DES MOINES, Iowa, Oct. 06, 2026 (GLOBE NEWSWIRE) — The retirement landscape has fundamentally changed for Gen X and Millennials, according to a new survey conducted by Harris Poll on behalf of Athene. Facing fewer pensions, greater market uncertainty and heightened concern about health care costs, inflation and Social Security, today’s pre-retirees are viewing and building a dramatically different model of retirement than the generations before them.

More than eight in 10 respondents (83%) say their generation faces retirement challenges previous generations did not, while 76% believe the U.S. retirement system was designed for a previous generation. Nearly two-thirds (61%) say they have fewer guaranteed retirement-income options than prior generations, and 63% are concerned Social Security will run out of funds before they begin collecting benefits.

“Greater awareness of the need for retirement savings means that the biggest questions most retirement savers face today are whether they will outlive their savings and how they can turn their savings into reliable income that lasts,” said Sean Brennan, Co-President, Athene USA. “Retirement savers have fewer traditional sources of guaranteed income, such as pensions, while managing greater uncertainty in this economic environment. Gen X and Millennials are looking for solutions to help navigate their future with confidence, flexibility and a greater sense of control over their financial futures.”

Rising Costs Create a New Set of Retirement Pressures

The survey of more than 2,000 U.S. adults ages 40–61 with at least $100,000 in investable assets and household income of $50,000 or more highlights the economic uncertainty regarding preparation and expectations for retirement. The top concern – two-thirds of respondents (67%) – is rising health care costs while 62% cite inflation as a major concern.

Those pressures are already influencing the ability to save. Half of respondents (50%) identify inflation as a top barrier to retirement saving, followed by day-to-day expenses (39%) and health care costs (32%).

Guaranteed Income Has Wide Appeal, but Is Not Widely Understood

The findings point to a significant opportunity to help retirement savers better understand options for creating dependable retirement income. Eighty-six percent of those who know what annuities are say they offer benefits that are appealing. Yet only 23% have purchased an annuity. However, with greater understanding, 80% say they would consider purchasing an annuity if they knew more about them. At the same time, more than half (53%) say annuities are too complex.

“These findings reinforce the broad appeal of guaranteed income solutions, as well as the need to create greater understanding of their benefits,” said Mike Downing, Co-President, Athene USA. “Annuities are a vital retirement tool that can complement savings, investments and Social Security to create a more resilient retirement plan.”

While respondents express a desire for security, their retirement plans often remain incomplete. Only 40% say they have planned for how to convert their accumulated savings into income in retirement, and just 29% say they have fully accounted for the length of their retirement in their financial planning. In addition, 85% of survey respondents found guaranteed monthly income through a 401(k) appealing, demonstrating a clear desire for pension-like features in the defined contribution ecosystem.

“Retirement savers shouldn’t need to become investment experts on the day they retire,” said Rebecca Tadikonda, CEO, Vitera. “Retirees need solutions that simplify their transition from saving to spending so they can confidently enjoy the retirement they worked hard for.”

Despite the challenges, respondents remain cautiously optimistic about their own financial security in retirement. Thirty-eight percent say they are somewhat confident in their ability to achieve retirement financial security, while 32% are very confident and 21% are extremely confident. Nine percent say they are not at all confident.

Methodology

This survey was conducted online within the United States by Harris Poll on behalf of Athene from June 26 through July 7, 2026, among 2,022 U.S. residents ages 40–61 with at least $100,000 in investable assets and household income of at least $50,000. Results have been weighted where necessary to bring them into line with their actual proportions in the population.

About Athene

Athene is the leading retirement solutions company with $473 billion of total assets as of June 30, 2026, and operations in the United States, Bermuda, Canada, and Japan. Athene is focused on providing financial security to individuals by offering an attractive suite of retirement income and savings products and also serves as a solutions provider to corporations. For more information, please visit www.athene.com.

Contact

Alyssa Castelli
Director, External Relations
+1 (646) 768-7304
Alyssa.castelli@athene.com

Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort. The event will provide an overview of the PDS0301 trial in patients with second and third line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases. These MSS patients constitute the majority of mCRC, a population in which immunotherapy has been mostly ineffective.

PDS0301 is an investigational IL-12 immunocytokine designed using an antibody that binds to necrotic DNA that is found within tumors. PDS0301 specifically targets and delivers the IL-12 into the tumor to promote T cell and natural killer (NK) cell infiltration into the tumor, as well as localized anti-tumor activation of both T cells and NK cells.

A live question and answer session will follow the formal presentations.

Register & Attend

Date:	Thursday, October 15, 2026
Time:	8:00 AM ET
Registration:	Click Here

Jonathan M. Hernandez, M.D., Investigator, Surgical Oncology Program, NCI/CCR

Dr. Hernandez graduated from medical school with honors from the University of Florida and completed general surgery training at the University of South Florida. During his residency, Dr. Hernandez spent two years at the Moffitt Cancer Center and Research Institute interrogating molecular diagnostics for liver metastases and miRNA-mediated mechanisms of metastatic spread. Following residency, Dr. Hernandez completed fellowship training in both surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center. During his fellowships, Dr. Hernandez spent an additional two years in dedicated basic research studying metastatic colonization as a scholar in the Cell Biology Program of the Sloan Kettering Institute and as a visiting investigator in the Cell and Developmental Biology Department of Weill Medical College of Cornell University. The Hernandez lab studies hepatic metastases and has been the home to twenty surgical residents since its establishment at the NIH in 2016. Dr. Hernandez has authored over 175 peer-reviewed publications and has contributed book chapters in numerous authoritative surgical texts.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. PDS Biotechnology owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.

The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune^® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  
Versamune^® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)

MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities.

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated in the financing.

DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, representing approximately 5.0% of Telomir’s outstanding common stock. His additional $1.0 million investment further increases his investment in Telomir as the Company advances its lead program into clinical development.

“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir,” said John Paul DeJoria. “Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”

Alexander Capital, L.P. acted as placement agent for the financing. The Company expects to receive aggregate gross proceeds of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Financing Terms

Under the terms of the financing, Telomir issued 4,843,300 shares of common stock at a purchase price of $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price (VWAP). The financing resulted in aggregate gross proceeds to the Company of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Investors in the financing purchased common stock at a fixed price, with no accompanying investor warrants, convertible securities, or variable-price or reset features.

The securities were issued in a private placement. Telomir has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued in the financing, subject to the terms of the Registration Rights Agreement.

The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.

“We have been very deliberate about how and when we access the capital markets,” said Erez Aminov, Chairman and CEO of Telomir. “Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”

Strengthening Telomir’s Position for Clinical Execution

The financing comes as Telomir advances Telomir-Zn, its lead investigational oral small molecule, into human clinical evaluation. The U.S. Food and Drug Administration has cleared Telomir’s Investigational New Drug (IND) application for Telomir-Zn, enabling the Company to proceed with its first-in-human Phase 1/2 clinical trial in patients with advanced or metastatic TNBC.

TNBC is an aggressive form of breast cancer defined by the absence of three common therapeutic targets, estrogen receptors, progesterone receptors, and HER2, limiting the applicability of many targeted treatments used in other forms of breast cancer. Patients with advanced or metastatic disease continue to face a significant need for additional treatment options.

The multicenter, open-label Phase 1/2 study is designed to move Telomir-Zn from initial human dosing through dose selection and into an efficacy-focused expansion. The Phase 1 portion will evaluate safety, tolerability, and dose selection while also assessing pharmacodynamic biomarkers and preliminary signals of antitumor activity. The Phase 2 expansion is designed to build on those findings with a greater focus on efficacy, providing an initial clinical proof-of-concept assessment of Telomir-Zn in advanced or metastatic TNBC.

A New Epigenetic Approach to Treating Cancer

Telomir-Zn is being developed as a potentially first-in-class oral epigenetic therapy designed to modulate intracellular metal homeostasis, particularly iron and copper, and influence gene-control pathways implicated in cancer. Preclinical studies have demonstrated inhibition of multiple iron-dependent histone demethylases (KDMs), supporting the Company’s hypothesis that Telomir-Zn may help restore more normal epigenetic regulation and potentially reactivate tumor-suppressor pathways that cancer has silenced.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Private Placement Disclosure

The securities described in this press release are being offered and sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement, subject to the terms and conditions of the applicable registration rights agreement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

SPRINGFIELD, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the fourth quarter ended July 25, 2026.

Fourth Quarter of Fiscal 2026 Highlights

• Net income of $13.6 million, or $0.92 per Class A diluted share
• Sales and same store sales each increased 1.6%
• Same store digital sales increased approximately 6%

Year-To-Date Fiscal 2026 Highlights

• Net income of $52.5 million, or $3.54 per Class A diluted share
• Sales increased 3.7% and same store sales increased 2.2%
• Same store digital sales increased approximately 11%

Fourth Quarter of Fiscal 2026 Results

Sales were $609.6 million in the 13 weeks ended July 25, 2026 compared to $599.7 million in the 13 weeks ended July 26, 2025. Sales increased due primarily to same store sales growth of 1.6% and the opening of our East Orange, NJ replacement store on May 27, 2026. Same store sales increased due primarily to digital sales growth, strong performance in fresh and pharmacy departments, and continued growth in recently remodeled and replacement stores. These increases were partially offset by egg price deflation, competitive store openings and sales cannibalization from the East Orange replacement store. New stores, replacement stores and stores with banner changes are included in same store sales in the quarter after the store has been in operation for four full quarters. Store renovations and expansions are included in same store sales immediately.

Gross profit as a percentage of sales increased to 28.24% in the 13 weeks ended July 25, 2026 compared to 28.17% in the 13 weeks ended July 26, 2025 due primarily to increased departmental gross margin percentages (.28%), largely offset by an unfavorable change in product mix (.08%), lower patronage dividends and other rebates received from Wakefern (.04%), increased promotional spending (.04%) and increased warehouse assessment charges from Wakefern (.03%). The increase in department gross margin is due primarily to improvements in shrink and commissary operations.

Operating and administrative expense as a percentage of sales increased to 23.92% in the 13 weeks ended July 25, 2026 compared to 23.11% in the 13 weeks ended July 26, 2025. Adjusted operating and administrative expense as a percentage of sales increased to 23.92% in the 13 weeks ended July 25, 2026 compared to 23.34% in the 13 weeks ended July 26, 2025. The increase in Adjusted operating and administrative expense is due primarily to higher employee costs (.16%), store pre-opening costs (.09%), external service, technology and payment processing costs (.08%), occupancy costs (.08%), facility insurance premiums (.07%), legal and other professional fees (.06%), and non-recurring costs associated with fire and power outage incidents (.05%). These increases were partially offset by lower advertising costs (.07%).

Depreciation and amortization expense increased in the 13 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to capital expenditures.

Interest expense decreased in the 13 weeks ended July 25, 2026 compared to the comparative prior year fiscal period due primarily to lower average outstanding debt balances.

Interest income decreased in the 13 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower interest rates on variable rate notes receivable from Wakefern and demand deposits invested at Wakefern.

The Company’s effective income tax rate was 30.6% in the 13 weeks ended July 25, 2026 compared to 31.4% in the 13 weeks ended July 26, 2025.

Net income was $13.6 million in the 13 weeks ended July 25, 2026 compared to $15.5 million in the 13 weeks ended July 26, 2025. Adjusted net income was $13.6 million in the 13 weeks ended July 25, 2026 compared to $15.6 million in the 13 weeks ended July 26, 2025.

Year-To-Date Fiscal 2026 Results

Sales were $2.406 billion in the 52 weeks ended July 25, 2026 compared to $2.321 billion in the 52 weeks ended July 26, 2025. Sales increased due primarily to same store sales growth of 2.2% and the openings of the Watchung, NJ and East Orange, NJ replacement stores on April 9, 2025 and May 27, 2026, respectively. Same store sales increased due primarily to digital sales growth, strong performance in fresh and pharmacy departments, and continued growth in remodeled and replacement stores. These increases were partially offset by egg price deflation and sales cannibalization from the Watchung replacement store.

Gross profit as a percentage of sales decreased to 28.17% in the 52 weeks ended July 25, 2026 compared to 28.57% in the 52 weeks ended July 26, 2025 due primarily to lower patronage dividends and other rebates received from Wakefern (.32%), an unfavorable change in product mix (.07%) and increased promotional spending (.05%), partially offset by increased departmental gross margin percentages (.07%).

Operating and administrative expense as a percentage of sales increased to 24.06% in the 52 weeks ended July 25, 2026 compared to 23.92% in the 52 weeks ended July 26, 2025. Adjusted operating and administrative expense as a percentage of sales increased to 24.05% in the 52 weeks ended July 25, 2026 compared to 23.98% in the 52 weeks ended July 26, 2025. The increase in Adjusted operating and administrative expense is due primarily to higher legal and other professional fees (.12%), utility, repair and maintenance costs (.10%), facility insurance costs (.06%) and store pre-opening costs (.06%). These increases were largely offset by lower employee costs (.13%), lower advertising costs (.10%) and short-term rental income (.05%).

Depreciation and amortization expense increased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to capital expenditures.

Interest expense decreased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower average outstanding debt balances.

Interest income decreased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower interest rates on variable rate notes receivable from Wakefern and demand deposits invested at Wakefern.

The Company’s effective income tax rate was 28.8% in the 52 weeks ended July 25, 2026 compared to 31.1% in the 52 weeks ended July 26, 2025. The decline in the effective tax rate was primarily due to the excess tax benefit from vested stock-based compensation in the 52 weeks ended July 25, 2026.

Net income was $52.5 million in the 52 weeks ended July 25, 2026 compared to $56.4 million in the 52 weeks ended July 26, 2025. Adjusted net income was $52.7 million in the 52 weeks ended July 25, 2026 compared to $56.4 million in the 52 weeks ended July 26, 2025.

Village Super Market, Inc. operates a chain of 34 supermarkets in New Jersey, New York, Maryland and Pennsylvania under the ShopRite and Fairway banners and three Gourmet Garage specialty markets in New York City.

Forward Looking Statements

All statements, other than statements of historical fact, included in this Press Release are or may be considered forward-looking statements within the meaning of federal securities law. The Company cautions the reader that there is no assurance that actual results or business conditions will not differ materially from future results, whether expressed, suggested or implied by such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect developments or information obtained after the date hereof. The following are among the principal factors that could cause actual results to differ from the forward-looking statements: general economic conditions; competitive pressures from the Company’s operating environment; the ability of the Company to maintain and improve its sales and margins; the ability to attract and retain qualified associates; the availability of new store locations; the availability of capital; the liquidity of the Company; the success of operating initiatives; consumer spending patterns; the impact of changing energy prices; increased cost of goods sold, including increased costs from the Company’s principal supplier, Wakefern; disruptions or changes in Wakefern’s operations; the results of litigation; the results of tax examinations; the results of union contract negotiations; competitive store openings and closings; labor shortages; disruptions to supply chains; and other factors detailed herein and in the Company’s filings with the SEC.

The Company’s consolidated financial statements are presented in accordance with generally accepted accounting principles (“GAAP”). We provide non-GAAP measures, including Adjusted net income and Adjusted operating and administrative expenses as management believes these supplemental measures are useful to investors and analysts. These non-GAAP financial measures should not be reviewed in isolation or considered as a substitute for our financial results as reported in accordance with GAAP, nor as an alternative to net income, operating and administrative expense or any other GAAP measure of performance. Management believes Adjusted net income and Adjusted operating and administrative expense are useful to investors because they provide supplemental measures that exclude the financial impact of certain items that affect period-to-period comparability. Management and the Board of Directors use these measures as they provide greater transparency in assessing ongoing operating performance on a period-to-period basis. Other companies may have different definitions of non-GAAP measures and provide for different adjustments, and comparability to the Company’s results of operations may be impacted by such differences. The Company’s presentation of non-GAAP measures should not be construed as an implication that its future results will be unaffected by unusual or non-recurring items.

VILLAGE SUPER MARKET, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited)
	13 Weeks Ended								52 Weeks Ended
	July 25, 2026				July 26, 2025				July 25, 2026				July 26, 2025
Sales	$	609,568			$	599,674			$	2,405,707			$	2,320,690
Cost of sales		437,453				430,773				1,727,956				1,657,724
Gross profit		172,115				168,901				677,751				662,966
Operating and administrative expense		145,825				138,581				578,928				555,038
Depreciation and amortization expense		8,944				8,640				34,507				34,398
Impairment of assets		—				1,462				—				1,462
Operating income		17,346				20,218				64,316				72,068
Interest expense		839				879				3,382				3,751
Interest income		(3,117	)			(3,274	)			(12,689	)			(13,502	)
Income before income taxes		19,624				22,613				73,623				81,819
Income taxes		6,007				7,093				21,168				25,439
Net income	$	13,617			$	15,520			$	52,455			$	56,380
Net income per share:
Class A common stock:
Basic	$	1.02			$	1.17			$	3.94			$	4.24
Diluted		0.92				1.05				3.54				3.81
Class B common stock:
Basic	$	0.66			$	0.76			$	2.56			$	2.75
Diluted		0.66				0.76				2.56				2.75
Gross profit as a % of sales		28.24	%			28.17	%			28.17	%			28.57	%
Operating and administrative expense as a % of sales		23.92	%			23.11	%			24.06	%			23.92	%

VILLAGE SUPER MARKET, INC.
RECONCILIATION OF NON-GAAP MEASURES
(In thousands) (Unaudited)

The following table reconciles Net income to Adjusted net income and Operating and administrative expenses to Adjusted operating and administrative expenses:

	13 Weeks Ended								52 Weeks Ended
	July 25, 2026				July 26, 2025				July 25, 2026				July 26, 2025
Net Income	$	13,617			$	15,520			$	52,455			$	56,380
Adjustments to Operating and Administrative Expenses:
Pension settlement charge (gain) (1)		—				(874	)			338				(874	)
Rent concession (2)		—				(517	)			—				(517	)
Adjustments to Impairment of Assets:
Impairment of assets (3)		—				1,462				—				1,462
Adjustments to Income Taxes:
Tax impact of special items		—				(22	)			(105	)			(22	)
Adjusted net income	$	13,617			$	15,569			$	52,688			$	56,429
Operating and administrative expenses	$	145,825			$	138,581			$	578,928			$	555,038
Adjustments to operating and administrative expenses		—				1,391				(338	)			1,391
Adjusted operating and administrative expenses	$	145,825			$	139,972			$	578,590			$	556,429
Adjusted operating and administrative expenses as a % of sales		23.92	%			23.34	%			24.05	%			23.98	%

(1) Fiscal 2026 pension settlement charge relates to the termination of a Company-sponsored plan. Fiscal 2025 pension settlement gain relates to lump payments made under an unfunded, non-qualified company sponsored defined benefit plan. 
(2) Fiscal 2025 includes income related to rent concessions received on one store location to compensate for disruption in operations during redevelopment of the retail center. 
(3) Fiscal 2025 includes non-cash impairment charges on the long-lived assets of one Gourmet Garage store and real estate assets classified as held for sale.

Contact:	John Van Orden, CFO
	(973) 467-2200
	villageinvestorrelations@wakefern.com

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,151,990	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,151,990	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	1,480	230.01p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,151,990	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,151,990	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	1,480	230.01p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Median time from sign-up to a working AI sales agent falls from approximately five hours to about four minutes in Sky’s first days in production

Moves SalesCloser toward a scalable self-serve model designed to lower customer acquisition cost and support long-term gross margin objectives

Company also announces digital marketing and investor awareness campaign

VANCOUVER, BC, Oct. 06, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, today announced the commercial launch of Sky, a conversational assistant that lets businesses build, launch and manage AI sales agents simply by talking to it. Since going into production on September 18, 2026, early Company data shows Sky has reduced the median time from customer sign-up to a first working AI sales agent from approximately five hours to about four minutes. The Company believes Sky is a key step in scaling SalesCloser through self-serve adoption, reducing the need for manual onboarding and sales-assisted setup.

A new customer simply tells Sky about their business. Sky reads the customer’s website, builds the agent’s knowledge base automatically, and applies industry-specific sales frameworks, terminology and objection handling for that vertical. The result is a test-ready AI sales agent in minutes, without forms, menus or technical setup.

After onboarding, Sky stays on as Sky Copilot, an in-dashboard assistant that makes changes on request. Customers can update what their agents say, launch campaigns and adjust settings by asking, without submitting support requests or relying on technical staff. The launch also introduces Agentic Integrations, an open connection model that enables agents to schedule meetings, update customer relationship management (“CRM”) records, and trigger post-call workflows across third-party tools.

Early results: In the eleven days following Sky’s production launch, the median time from sign-up to first agent fell from approximately 295 minutes to approximately 4 minutes, based on the Company’s internal product analytics.

“Every business wants AI working in its sales process, but most get stuck at setup,” said Ali Tajskandar, CEO of SalesCloser. “Sky removes that barrier. A business can now describe what it sells and have a live, industry-trained AI sales agent ready in minutes rather than hours. That matters for our customers, and it matters for our model: self-serve onboarding is how we believe SalesCloser scales efficiently, reaching more businesses with lower acquisition costs and supporting our long-term gross margin objectives.”

See it for yourself: Investors, prospective customers and partners can talk to a live SalesCloser AI sales agent at https://salescloser.ai by selecting “Talk to an agent, live.”

Engagement of Investor Relations Services Provider

The Company has also engaged SmallCapVoice.com, Inc. (“SmallCapVoice”), an arm’s-length, privately held Texas investor-awareness firm based in Cedar Park, Texas and controlled by its founder and CEO, Stuart Smith, to provide social media, influencer, video and investor outreach services for an initial 30-day term, subject to TSX Venture Exchange acceptance. The Company may renew the term, at its option, for up to two further 30-day periods. The fee for the initial term is US$5,500 payable from working capital, and US$5,500 for each renewal term. To the Company’s knowledge, SmallCapVoice holds no securities of the Company and has no right or intent to acquire any.

About SalesCloser
SalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company’s platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser’s agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform is designed to help organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and is intended to deliver consistent customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue, while continuing to develop its AI capabilities. The Company’s technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker “SCAI”, on the OTCQB Venture Market under the ticker “SCTLF”, and on the Frankfurt Stock Exchange under the ticker “MJ5”. For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai

Corporate Contact
Adrian Lim, CFO
Email: investors@salescloser.ai
Phone: 778-655-4329

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
SCAI@arxhq.com

Forward-Looking Statements
Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about: the commercial launch, features, capabilities, performance, and anticipated benefits of Sky, Sky Copilot, Agentic Integrations, and industry vertical skill matching; early-period and future results of Sky; the expected reduction in onboarding time, technical overhead, and time-to-value for customers; the ability of AI agents to interact with third-party business systems; customer adoption, engagement, and retention; the Company’s technology roadmap; future growth and increased use of products incorporating artificial intelligence; the Company’s ability to scale operations and expand across diverse industry verticals; expectations regarding the universal applicability and market potential of Sky; reduction in account drop-off; acceleration of trial-to-paid conversion; shortened sales cycles; lower customer acquisition costs; revenue growth, recurring SaaS revenue, and long-term gross margin targets; technology development initiatives; commercial expansion and go-to-market strategies; future profitability; business opportunities, objectives, and prospects; TSX Venture Exchange approval of the Company’s agreement with SmallCapVoice; the services to be provided by SmallCapVoice; any benefits that may be realized by the Company from its engagement with SmallCapVoice; the Company’s exercise of any renewal term pursuant to its engagement with SmallCapVoice, and future events and performance. Sentences containing words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “may”, “will”, “project”, “predict”, “potential”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on material assumptions, including that Sky and related features will perform as designed, continued demand for conversational AI, the Company’s ability to attract customers and platform partners, competition within the AI space and the ability of Sky to compete effectively against other products and services, and general economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and based on current market trends and analysis of management, such statements are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to: risks that Sky, Sky Copilot, Agentic Integrations, or vertical skill matching do not perform as expected, experience technical difficulties, or fail to achieve commercial adoption; risks that early-period results for Sky, which are based on the Company’s internal product analytics over a limited period, may not be indicative of future performance; risks associated with delays in the development or rollout of new features; changes to SalesCloser and other products’ revenue and profitability; changes to customer preferences and demand for conversational AI; risks that the Company may not obtain TSX Venture Exchange approval of its engagement with SmallCapVoice; that the Company may not realize the benefit expected from its engagement with SmallCapVoice; competition from larger technology companies or other conversational AI providers; reliance on third-party service providers, cloud infrastructure, and software platforms; risks that third parties develop competing technology or assert intellectual property infringement; data security, privacy, and regulatory compliance risks; economic uncertainty, inflation, interest rate fluctuations, and recessionary risks; and the additional risk factors discussed in the continuous disclosure materials of the Company available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update or revise them, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Median time from sign-up to a working AI sales agent falls from approximately five hours to about four minutes in Sky’s first days in production

Moves SalesCloser toward a scalable self-serve model designed to lower customer acquisition cost and support long-term gross margin objectives

Company also announces digital marketing and investor awareness campaign

VANCOUVER, BC, Oct. 06, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, today announced the commercial launch of Sky, a conversational assistant that lets businesses build, launch and manage AI sales agents simply by talking to it. Since going into production on September 18, 2026, early Company data shows Sky has reduced the median time from customer sign-up to a first working AI sales agent from approximately five hours to about four minutes. The Company believes Sky is a key step in scaling SalesCloser through self-serve adoption, reducing the need for manual onboarding and sales-assisted setup.

A new customer simply tells Sky about their business. Sky reads the customer’s website, builds the agent’s knowledge base automatically, and applies industry-specific sales frameworks, terminology and objection handling for that vertical. The result is a test-ready AI sales agent in minutes, without forms, menus or technical setup.

After onboarding, Sky stays on as Sky Copilot, an in-dashboard assistant that makes changes on request. Customers can update what their agents say, launch campaigns and adjust settings by asking, without submitting support requests or relying on technical staff. The launch also introduces Agentic Integrations, an open connection model that enables agents to schedule meetings, update customer relationship management (“CRM”) records, and trigger post-call workflows across third-party tools.

Early results: In the eleven days following Sky’s production launch, the median time from sign-up to first agent fell from approximately 295 minutes to approximately 4 minutes, based on the Company’s internal product analytics.

“Every business wants AI working in its sales process, but most get stuck at setup,” said Ali Tajskandar, CEO of SalesCloser. “Sky removes that barrier. A business can now describe what it sells and have a live, industry-trained AI sales agent ready in minutes rather than hours. That matters for our customers, and it matters for our model: self-serve onboarding is how we believe SalesCloser scales efficiently, reaching more businesses with lower acquisition costs and supporting our long-term gross margin objectives.”

See it for yourself: Investors, prospective customers and partners can talk to a live SalesCloser AI sales agent at https://salescloser.ai by selecting “Talk to an agent, live.”

Engagement of Investor Relations Services Provider

The Company has also engaged SmallCapVoice.com, Inc. (“SmallCapVoice”), an arm’s-length, privately held Texas investor-awareness firm based in Cedar Park, Texas and controlled by its founder and CEO, Stuart Smith, to provide social media, influencer, video and investor outreach services for an initial 30-day term, subject to TSX Venture Exchange acceptance. The Company may renew the term, at its option, for up to two further 30-day periods. The fee for the initial term is US$5,500 payable from working capital, and US$5,500 for each renewal term. To the Company’s knowledge, SmallCapVoice holds no securities of the Company and has no right or intent to acquire any.

About SalesCloser
SalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company’s platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser’s agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform is designed to help organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and is intended to deliver consistent customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue, while continuing to develop its AI capabilities. The Company’s technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker “SCAI”, on the OTCQB Venture Market under the ticker “SCTLF”, and on the Frankfurt Stock Exchange under the ticker “MJ5”. For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai

Corporate Contact
Adrian Lim, CFO
Email: investors@salescloser.ai
Phone: 778-655-4329

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
SCAI@arxhq.com

Forward-Looking Statements
Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about: the commercial launch, features, capabilities, performance, and anticipated benefits of Sky, Sky Copilot, Agentic Integrations, and industry vertical skill matching; early-period and future results of Sky; the expected reduction in onboarding time, technical overhead, and time-to-value for customers; the ability of AI agents to interact with third-party business systems; customer adoption, engagement, and retention; the Company’s technology roadmap; future growth and increased use of products incorporating artificial intelligence; the Company’s ability to scale operations and expand across diverse industry verticals; expectations regarding the universal applicability and market potential of Sky; reduction in account drop-off; acceleration of trial-to-paid conversion; shortened sales cycles; lower customer acquisition costs; revenue growth, recurring SaaS revenue, and long-term gross margin targets; technology development initiatives; commercial expansion and go-to-market strategies; future profitability; business opportunities, objectives, and prospects; TSX Venture Exchange approval of the Company’s agreement with SmallCapVoice; the services to be provided by SmallCapVoice; any benefits that may be realized by the Company from its engagement with SmallCapVoice; the Company’s exercise of any renewal term pursuant to its engagement with SmallCapVoice, and future events and performance. Sentences containing words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “may”, “will”, “project”, “predict”, “potential”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on material assumptions, including that Sky and related features will perform as designed, continued demand for conversational AI, the Company’s ability to attract customers and platform partners, competition within the AI space and the ability of Sky to compete effectively against other products and services, and general economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and based on current market trends and analysis of management, such statements are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to: risks that Sky, Sky Copilot, Agentic Integrations, or vertical skill matching do not perform as expected, experience technical difficulties, or fail to achieve commercial adoption; risks that early-period results for Sky, which are based on the Company’s internal product analytics over a limited period, may not be indicative of future performance; risks associated with delays in the development or rollout of new features; changes to SalesCloser and other products’ revenue and profitability; changes to customer preferences and demand for conversational AI; risks that the Company may not obtain TSX Venture Exchange approval of its engagement with SmallCapVoice; that the Company may not realize the benefit expected from its engagement with SmallCapVoice; competition from larger technology companies or other conversational AI providers; reliance on third-party service providers, cloud infrastructure, and software platforms; risks that third parties develop competing technology or assert intellectual property infringement; data security, privacy, and regulatory compliance risks; economic uncertainty, inflation, interest rate fluctuations, and recessionary risks; and the additional risk factors discussed in the continuous disclosure materials of the Company available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update or revise them, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Hong Kong, Oct. 06, 2026 (GLOBE NEWSWIRE) — Green Circle Decarbonize Technology Limited (the “Company”) (NYSE: GCDT), a premier provider of customized energy-saving solutions, today announced its expansion into the artificial intelligence (“AI”) data center infrastructure market in the near future. The Company is launching next-generation, ultra-low energy liquid cooling systems designed for high-density AI computing sector.

As the expansion of global AI infrastructure increases the power demands and thermal management requirements, the traditional cooling methods are facing new efficiency challenges. In this regard, the Company has adapted its proprietary phase change materials (PCM-TES) and industrial machinery technologies to develop an optimized green liquid cooling solution. This technology is designed to help data centers improve power usage effectiveness and better manage operational energy costs.

The Company is currently in technical discussions and preliminary evaluations with industry participants and data center operators to conduct the research and development. Through these initiatives, the Company aimed to further advance sustainable technology in AI infrastructure, contributing to improved resource efficiency and cost reduction across the sector.

About Green Circle Decarbonize Technology Limited

Green Circle Decarbonize Technology Limited is a Cayman Islands holding company operating through its Hong Kong subsidiary, Boca International Limited. The Company is a provider of advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Green Circle Decarbonize Technology Limited

Investor Relations Department
Email: dr.richardchan@gmail.com